Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration-resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Clinical case reports. 2018 Jan 11*** epublish ***

Kota Shimokihara, Takashi Kawahara, Taisei Suzuki, Taku Mochizuki, Daiji Takamoto, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Masahiro Yao, Hiroji Uemura

Departments of Urology and Renal TransplantationYokohama City University Medical CenterYokohamaJapan., Department of HematologyYokohama City University Medical CenterYokohamaJapan., Department of UrologyYokohama City University Graduate School of MedicineYokohamaJapan.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe